全文获取类型
收费全文 | 26903篇 |
免费 | 2356篇 |
国内免费 | 63篇 |
专业分类
耳鼻咽喉 | 194篇 |
儿科学 | 1005篇 |
妇产科学 | 844篇 |
基础医学 | 3931篇 |
口腔科学 | 408篇 |
临床医学 | 3556篇 |
内科学 | 5018篇 |
皮肤病学 | 330篇 |
神经病学 | 3085篇 |
特种医学 | 523篇 |
外国民族医学 | 1篇 |
外科学 | 2522篇 |
综合类 | 366篇 |
一般理论 | 49篇 |
预防医学 | 3478篇 |
眼科学 | 430篇 |
药学 | 1806篇 |
中国医学 | 47篇 |
肿瘤学 | 1729篇 |
出版年
2023年 | 234篇 |
2022年 | 275篇 |
2021年 | 575篇 |
2020年 | 412篇 |
2019年 | 633篇 |
2018年 | 673篇 |
2017年 | 546篇 |
2016年 | 557篇 |
2015年 | 640篇 |
2014年 | 901篇 |
2013年 | 1280篇 |
2012年 | 1854篇 |
2011年 | 1906篇 |
2010年 | 1024篇 |
2009年 | 987篇 |
2008年 | 1600篇 |
2007年 | 1733篇 |
2006年 | 1744篇 |
2005年 | 1640篇 |
2004年 | 1608篇 |
2003年 | 1458篇 |
2002年 | 1348篇 |
2001年 | 375篇 |
2000年 | 312篇 |
1999年 | 336篇 |
1998年 | 303篇 |
1997年 | 245篇 |
1996年 | 198篇 |
1995年 | 186篇 |
1994年 | 143篇 |
1993年 | 163篇 |
1992年 | 233篇 |
1991年 | 207篇 |
1990年 | 184篇 |
1989年 | 185篇 |
1988年 | 174篇 |
1987年 | 161篇 |
1986年 | 145篇 |
1985年 | 143篇 |
1984年 | 131篇 |
1983年 | 134篇 |
1982年 | 124篇 |
1981年 | 107篇 |
1980年 | 117篇 |
1979年 | 118篇 |
1978年 | 76篇 |
1977年 | 75篇 |
1976年 | 80篇 |
1974年 | 78篇 |
1973年 | 94篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
William R. C. Knight Cara R. Baker Nyree Griffin Wahyu Wulaningsih Mark Kelly Andrew R. Davies James A. Gossage 《British journal of cancer》2021,124(10):1653
Background A high Mandard score implies a non-response to chemotherapy in oesophageal adenocarcinoma. However, some patients exhibit tumour volume reduction and a nodal response despite a high score. This study examines survival and recurrence patterns in these patients.Methods Clinicopathological factors were analysed using multivariable Cox regression assessing time to death and recurrence. Computed tomography-estimated tumour volume change was examined in a subgroup of consecutive patients.Results Five hundred and fifty-five patients were included. Median survival was 55 months (Mandard 1–3) and 21 months (Mandard 4 and 5). In the Mandard 4 and 5 group (332 patients), comparison between complete nodal responders and persistent nodal disease showed improved survival (90 vs 18 months), recurrence rates (locoregional 14.75 vs 28.74%, systemic 24.59 vs 48.42%) and circumferential resection margin positivity (22.95 vs 68.11%). Complete nodal response independently predicted improved survival (hazard ratio 0.34 (0.16–0.74). Post-chemotherapy tumour volume reduction was greater in patients with a complete nodal response (−16.3 vs −7.7 cm3, p = 0.033) with no significant difference between Mandard groups.Conclusion Patients with a complete nodal response to chemotherapy have significantly improved outcomes despite a poor Mandard score. High Mandard score does not correspond with a non-response to chemotherapy in all cases and patients with nodal downstaging may still benefit from adjuvant chemotherapy.Subject terms: Oesophageal cancer, Surgical oncology 相似文献
5.
6.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
7.
Mary Ann Richardson Helen M Chao Laura L Read James D Clelland Raymond F Suckow 《American journal of medical genetics. Part B, Neuropsychiatric genetics》2006,(2):195-197
Phenylketonuria (PKU), an inborn error of phenylalanine metabolism, has been shown to be a risk factor for tardive dyskinesia (TD). In male psychiatric patients there was a significant relationship between TD and measures of plasma phenylalanine following ingestion of a standardized phenylalanine dose that was indicative of higher brain availability of phenylalanine in patients with TD. In addition, a medical food formulation consisting of branched chain amino acids, which compete with phenylalanine for transport across the blood-brain barrier, has been demonstrated to be an efficacious treatment for TD. Cumulatively these findings suggested that TD was related to phenylalanine metabolism and thus that sequence variants in the gene for phenylalanine hydroxylase (PAH), the rate-limiting enzyme in the catabolism of phenylalanine, could be associated with TD susceptibility. Genetic screening of PAH in a group of 123 psychiatric patients revealed ten sequence polymorphisms and two mutations, but none appeared to be a significant risk factor for TD. 相似文献
8.
9.
10.